Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

lymphoma
cutaneous t-cell lymphoma
metastases
leukemia
anaplastic large cell lymphoma
  • 0 views
  • 27 Jan, 2021
  • 25 locations
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the

  • 0 views
  • 23 Jan, 2021
  • 1 location
Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma

This is a study for people who have been previously treated for Leukemia/Lymphoma. In particular, it is a study for people who have a type of Leukemia/Lymphoma that involves B cells (a type of white cell), which contain the cancer. This is a new approach for treatment of Leukemia/Lymphoma that …

tumor cells
cancer
lymphoma
leukemia
  • 71 views
  • 07 Nov, 2020
  • 1 location
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as selinexor, …

recurrent disease
lymphoma
chronic lymphocytic leukemia
beta-human chorionic gonadotropin
leukemia
  • 36 views
  • 08 Mar, 2021
  • 2 locations
Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of autologous anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.

  • 0 views
  • 16 Apr, 2021
  • 1 location
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

  • 0 views
  • 15 Mar, 2021
  • 1 location
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Background Some people with cancer have solid tumors. Others have refractory leukemia. This doesn t go away after treatment. Researchers want to see if a drug called PLX3397 can shrink tumors or stop them from growing. Objectives To find the highest safe dose and side effects of PLX3397. To see …

malignant peripheral nerve sheath tumor
hydroxyurea
monoclonal antibodies
measurable disease
filgrastim
  • 48 views
  • 16 Apr, 2021
  • 1 location
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.

residual tumor
follicular lymphoma
myeloproliferative disorder
oxygen saturation
leukemia
  • 42 views
  • 25 Jan, 2021
  • 1 location
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking …

follicular lymphoma
venetoclax
large b-cell lymphoma
chronic lymphocytic leukemia
leukemia
  • 12 views
  • 24 Jan, 2021
  • 2 locations
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate …

residual tumor
follicular lymphoma
residual disease
chronic lymphocytic leukemia
myeloproliferative disorder
  • 58 views
  • 27 Jan, 2021
  • 1 location